FBR & Co restated their outperform rating on shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) in a research report sent to investors on Wednesday. They currently have a $9.00 target price on the stock.
AUPH has been the topic of a number of other research reports. Canaccord Genuity reissued a buy rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a research note on Saturday, October 8th. HC Wainwright reissued a buy rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a research note on Wednesday, October 5th. Finally, Leerink Swann reissued an outperform rating and set a $7.00 price target on shares of Aurinia Pharmaceuticals in a research note on Monday, October 3rd. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of Buy and an average price target of $7.75.
Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at 4.16 on Wednesday. Aurinia Pharmaceuticals has a 1-year low of $1.42 and a 1-year high of $5.69. The firm’s market capitalization is $146.79 million. The company’s 50-day moving average price is $2.77 and its 200 day moving average price is $2.83.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Lombard Odier Asset Management USA Corp raised its position in shares of Aurinia Pharmaceuticals by 2.8% in the second quarter. Lombard Odier Asset Management USA Corp now owns 102,294 shares of the company’s stock valued at $283,000 after buying an additional 2,813 shares during the period. Creative Planning purchased a new position in shares of Aurinia Pharmaceuticals during the third quarter valued at $181,000. Finally, Abingworth LLP raised its position in shares of Aurinia Pharmaceuticals by 479.8% in the second quarter. Abingworth LLP now owns 512,036 shares of the company’s stock valued at $1,388,000 after buying an additional 423,729 shares during the period. 20.04% of the stock is currently owned by institutional investors and hedge funds.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.